Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Defining a mutational signature for endometrial cancer screening and early detection.

Costas L, Palomero L, Benavente Y, Guardiola M, Frias-Gomez J, Pavón MÁ, Climent M, Martinez JM, Barahona M, Salinas M, Pineda M, Bianchi I, Reventós J, Capellà G, Diaz M, Vidal A, Piulats JM, Ponce J, Brunet J, Bosch FX, Matias-Guiu X, Alemany L, de Sanjosé S, Aytés Á; Screenwide Team.

Cancer Epidemiol. 2019 Aug;61:129-132. doi: 10.1016/j.canep.2019.06.003. Epub 2019 Jun 22.

PMID:
31238232
2.

New perspectives on screening and early detection of endometrial cancer.

Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pavón MÁ, Martínez JM, Climent M, Barahona M, Canet J, Paytubi S, Salinas M, Palomero L, Bianchi I, Reventós J, Capellà G, Diaz M, Vidal A, Piulats JM, Aytés Á, Ponce J, Brunet J, Bosch FX, Matias-Guiu X, Alemany L, de Sanjosé S; Screenwide Team.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32514. [Epub ahead of print] Review.

PMID:
31199503
3.

BRCA2 and Other DDR Genes in Prostate Cancer.

Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E.

Cancers (Basel). 2019 Mar 12;11(3). pii: E352. doi: 10.3390/cancers11030352. Review.

4.

NSD2 is a conserved driver of metastatic prostate cancer progression.

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM, Califano A, Abate-Shen C.

Nat Commun. 2018 Dec 5;9(1):5201. doi: 10.1038/s41467-018-07511-4.

5.

Epigenetic Regulation in Prostate Cancer Progression.

Ruggero K, Farran-Matas S, Martinez-Tebar A, Aytes A.

Curr Mol Biol Rep. 2018;4(2):101-115. doi: 10.1007/s40610-018-0095-9. Epub 2018 Apr 18. Review.

6.

Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.

Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A.

Clin Cancer Res. 2018 Aug 1;24(15):3755-3766. doi: 10.1158/1078-0432.CCR-17-1898. Epub 2018 Apr 4.

7.

Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.

Mitrofanova A, Aytes A, Zou M, Shen MM, Abate-Shen C, Califano A.

Cell Rep. 2015 Sep 29;12(12):2060-71. doi: 10.1016/j.celrep.2015.08.051. Epub 2015 Sep 17.

8.

Characterization of an acromesomelic dysplasia, Grebe type case: novel mutation affecting the recognition motif at the processing site of GDF5.

Martinez-Garcia M, Garcia-Canto E, Fenollar-Cortes M, Aytes AP, Trujillo-Tiebas MJ.

J Bone Miner Metab. 2016 Sep;34(5):599-603. doi: 10.1007/s00774-015-0693-z. Epub 2015 Aug 15.

PMID:
26275437
9.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

10.

Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, Califano A, Abate-Shen C.

Cancer Cell. 2014 May 12;25(5):638-651. doi: 10.1016/j.ccr.2014.03.017.

11.

A molecular signature predictive of indolent prostate cancer.

Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, Le Magnen C, Guarnieri P, Sumazin P, Benson MC, Shen MM, Califano A, Abate-Shen C.

Sci Transl Med. 2013 Sep 11;5(202):202ra122. doi: 10.1126/scitranslmed.3006408. Erratum in: Sci Transl Med. 2013 Sep 18;5(203):203er9.

12.

ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, LeKaye HC, Koutcher JA, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15. doi: 10.1073/pnas.1303558110. Epub 2013 Aug 5.

13.

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.

Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 15;72(18):4765-76. Epub 2012 Jul 25.

14.

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 1;72(17):4483-93. doi: 10.1158/0008-5472.CAN-12-0283. Epub 2012 Jul 19.

15.

Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype.

Aytes A, Molleví DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A, Salazar R, Capellà G, Villanueva A.

Mol Carcinog. 2012 Sep;51(9):746-53. doi: 10.1002/mc.20843. Epub 2011 Aug 30.

PMID:
22125164
16.

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV, Guinó E, Chen H, Evans GJ, Mohan P, Català I, Petit A, Aguilar H, Villanueva A, Aytes A, Serra-Musach J, Rennert G, Lejbkowicz F, Peterlongo P, Manoukian S, Peissel B, Ripamonti CB, Bonanni B, Viel A, Allavena A, Bernard L, Radice P, Friedman E, Kaufman B, Laitman Y, Dubrovsky M, Milgrom R, Jakubowska A, Cybulski C, Gorski B, Jaworska K, Durda K, Sukiennicki G, Lubiński J, Shugart YY, Domchek SM, Letrero R, Weber BL, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, Roozendaal CE; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver C, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Eccles D, Douglas F, Brewer C, Nevanlinna H, Heikkinen T, Couch FJ, Lindor NM, Wang X, Godwin AK, Caligo MA, Lombardi G, Loman N, Karlsson P, Ehrencrona H, Wachenfeldt Av; SWE-BRCA, Barkardottir RB, Hamann U, Rashid MU, Lasa A, Caldés T, Andrés R, Schmitt M, Assmann V, Stevens K, Offit K, Curado J, Tilgner H, Guigó R, Aiza G, Brunet J, Castellsagué J, Martrat G, Urruticoechea A, Blanco I, Tihomirova L, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Deissler H, Varon-Mateeva R, Sutter C, Niederacher D, Imyamitov E, Sinilnikova OM, Stoppa-Lyonne D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Fert Ferrer S, Collonge-Rame MA, Mortemousque I; GEMO Study Collaborators, Spurdle AB, Beesley J, Chen X, Healey S; kConFab, Barcellos-Hoff MH, Vidal M, Gruber SB, Lázaro C, Capellá G, McGuffog L, Nathanson KL, Antoniou AC, Chenevix-Trench G, Fleisch MC, Moreno V, Pujana MA.

PLoS Biol. 2011 Nov;9(11):e1001199. doi: 10.1371/journal.pbio.1001199. Epub 2011 Nov 15.

17.

Ubiquitin ligases of the N-end rule pathway: assessment of mutations in UBR1 that cause the Johanson-Blizzard syndrome.

Hwang CS, Sukalo M, Batygin O, Addor MC, Brunner H, Aytes AP, Mayerle J, Song HK, Varshavsky A, Zenker M.

PLoS One. 2011;6(9):e24925. doi: 10.1371/journal.pone.0024925. Epub 2011 Sep 13.

18.

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.

Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M.

Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. doi: 10.1073/pnas.1014720108. Epub 2011 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2017 Jan 17;:.

19.

Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features.

Unger S, Lausch E, Rossi A, Mégarbané A, Sillence D, Alcausin M, Aytes A, Mendoza-Londono R, Nampoothiri S, Afroze B, Hall B, Lo IF, Lam ST, Hoefele J, Rost I, Wakeling E, Mangold E, Godbole K, Vatanavicharn N, Franco LM, Chandler K, Hollander S, Velten T, Reicherter K, Spranger J, Robertson S, Bonafé L, Zabel B, Superti-Furga A.

Am J Med Genet A. 2010 Oct;152A(10):2543-9. doi: 10.1002/ajmg.a.33641.

PMID:
20830804
20.

PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts.

Molleví DG, Aytes A, Berdiel M, Padullés L, Martínez-Iniesta M, Sanjuan X, Salazar R, Villanueva A.

Mol Cancer. 2009 Jul 8;8:46. doi: 10.1186/1476-4598-8-46.

21.

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.

Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J, Capella G, Villanueva A.

Br J Cancer. 2008 Nov 18;99(10):1718-25. doi: 10.1038/sj.bjc.6604747. Epub 2008 Oct 28.

22.

Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.

Fernández-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytés A, Real FX, Capella G, Mayo MW, Espinosa L, Bigas A.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):276-81. Epub 2006 Dec 26. Erratum in: Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5650.

23.

Möbius sequence, hypogenitalism, cerebral, and skeletal malformations in two brothers.

Criado GR, Aytés AP.

Am J Med Genet. 1999 Oct 29;86(5):492-6.

PMID:
10508994

Supplemental Content

Support Center